Breaking Finance News

A report released today by Oddo Seydler Bank AG about MorphoSys (ETR:MOR) raises the target price to 66.00EUR

Yesterday MorphoSys (ETR:MOR) traded 0.00% even at 44.35EUR. The company’s 50-day moving average is 0.00EUR and its 200-day moving average is 0.00EUR. The last closing price is up 0.00% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 0 shares of MOR traded, down from an avg. volume of 42,448

In a report released on 10/06/2016 Oddo Seydler Bank AG increased the stock price target of MorphoSys (ETR:MOR) to 66.00EUR indicating a possible upside of 0.49%.

Previously on Wednesday October 05, 2016, Oddo Seydler Bank AG reported on MorphoSys (ETR:MOR) increased the target price from 0.00EUR to 66.00EUR. At the time, this indicated a possible upside of 0.49%.

Performance Chart

MorphoSys (ETR:MOR)

With a total market value of 0 EUR, MorphoSys has with a one year low of 0.00EUR and a one year high of 0.00EUR .

More About MorphoSys (ETR:MOR)

MorphoSys AG (MorphoSys) develops and commercializes antibodies for therapeutic applications. The Company's operating segments include Proprietary Development and Partnered Discovery. The Company develops new treatments for patients suffering from serious diseases. The Company has a total of approximately 100 individual therapeutic antibody programs, among which are in Phase III trials. MorphoSys has developed various technologies, which offer direct access to fully human antibodies for the treatment of diseases. The Company's technologies include HuCAL, which is a collection of billions of fully human antibodies and a system for their optimization, and Ylanthia, which is an antibody library in Fab format based on the concept for generating specific and fully human antibodies. It is evaluating the clinical development of approximately three cancer programs, including MOR208, MOR202 and MOR209/ES414.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.